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Hypomethylating agents decitabine and azacytidine are regarded as interchangeable in the
treatment of acute myeloid leukemia (AML). However, their mechanisms of action remain
incompletely understood, and predictive biomarkers for HMA efficacy are lacking. Here, we
show that the bioactive metabolite decitabine triphosphate, but not azacytidine triphosphate,
functions as activator and substrate of the triphosphohydrolase SAMHD1 and is subject to
SAMHD1-mediated inactivation. Retrospective immunohistochemical analysis of bone mar-
row specimens from AML patients at diagnosis revealed that SAMHD1 expression in leu-
kemic cells inversely correlates with clinical response to decitabine, but not to azacytidine.
SAMHD1 ablation increases the antileukemic activity of decitabine in AML cell lines, primary
leukemic blasts, and xenograft models. AML cells acquire resistance to decitabine partly by
SAMHD1 up-regulation. Together, our data suggest that SAMHD1 is a biomarker for the
stratified use of hypomethylating agents in AML patients and a potential target for the
treatment of decitabine-resistant leukemia.
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DNA hypomethylating agents (HMAs), including the aza-nucleosides decitabine (DAC, 5-aza-2′-deoxycytidine)and azacytidine (AZA, 5-azacytidine), have emerged as
less toxic alternative treatment options for myelodysplastic syn-
drome (MDS) and acute myeloid leukemia (AML) patients who
cannot tolerate intensive chemotherapy. Several clinical trials
have revealed a significant benefit of DAC and AZA treatment
over alternative care regimens (predominantly best supportive
care or low-dose Ara-C) with overall response rates ranging from
10 to 70%1–4. Because in some patients responses are restricted to
either of the drugs, predictive biomarkers for HMAs are urgently
needed to enable personalized drug selection. Currently, both
drugs are frequently considered to be equivalent in clinical
practice5–7. However, there is a lack of HMA head-to-head
comparisons, and the understanding of their mechanisms of
action is incomplete. Moreover, guadecitabine (SGI-110), a
dinucleotide of DAC and deoxyguanosine and DAC prodrug, is
under clinical investigation as additional HMA for AML
treatment8.
AZA and DAC are structurally related cytidine nucleoside
analogs (Fig. 1a) that become intracellularly activated by tri-
phosphorylation (Supplementary Fig. 1)9,10. DAC triphosphate
(DAC-TP) is exclusively incorporated into DNA, while AZA-
TP is incorporated primarily into RNA. However, about
10–35% of AZA are metabolized into DAC-TP, following the
intracellular conversion of AZA diphosphate (AZA-DP) by
ribonucleotide reductase (RNR) to DAC-DP (Supplementary
Fig. 1)11,12. AZA- and DAC-derived DAC-TP can therefore
exert identical effects, including depletion of DNA methyl-
transferases (DNMTs), suppression of DNA methylation, and
induction of DNA damage and apoptosis9,10. AZA-TP incor-
poration into RNA results in AZA-specific effects, such as
disruption of transcription and protein synthesis (Supplemen-
tary Fig. 1)9,10. Since suppression of DNA methylation was not
found to correlate well with HMA efficacy in AML and MDS
patients13,14, the exact modes of the antileukemic action of
AZA and DAC remain to be elucidated.
The sterile alpha motif and histidine-aspartate domain-con-
taining protein 1 (SAMHD1) is a 2′-deoxynucleoside-5′-tri-
phospohate (dNTP) triphosphohydrolase that cleaves
physiological dNTPs (but not ribose-based NTPs) into 2′-deox-
ynucleosides and inorganic triphosphate15,16. The tripho-
sphohydrolase activity of SAMHD1 requires the assembly of a
homotetramer complex, which is regulated by the binding of GTP
or dGTP to the allosteric site 1 (A1) and any canonical dNTP to
the allosteric site 2 (A2)17,18 (Supplementary Fig. 2a). Recently,
SAMHD1 was found to hydrolyze cytarabine triphosphate (Ara-
CTP) and several other nucleoside analog triphosphates used for
the treatment of leukemia19–21. Moreover, SAMHD1 was iden-
tified as a biomarker that is predictive for the clinical response of
AML patients to Ara-C-based therapy19,22. Independently of its
triphosphohydrolase function, SAMHD1 may further counteract
the activity of DNA-damaging drugs through promotion of a
cellular nuclease activity involved in DNA end resection, which
facilitates DNA double-strand break (DSB) repair by homologous
recombination (HR)23. However, the relevance of this additional
mechanism has not been investigated in the context of nucleoside
analog treatment of AML, yet.
Previous observations suggested that SAMHD1 interacts with
DAC-TP21 and influences DAC efficacy in leukemic cell lines24.
However, detailed mechanistic and functional studies are cur-
rently lacking and the effect of SAMHD1 on DAC or AZA
responses in a clinical context remains unknown. Therefore, we
here investigate the interaction of SAMHD1 with DAC-TP and
AZA-TP and the consequences that this may have on their
antileukemic activities in AML patients. We show that DAC-TP
is both an activator and a substrate of SAMHD1. Its tripho-
sphohydrolase activity, but not nuclease-promoting activity,
determines the therapeutic efficacy of DAC and SGI-110, while
that of AZA remains unaffected. Thus, SAMHD1 is a clinically
relevant DAC resistance factor and a predictive biomarker for
DAC (and SGI-110) stratification in AML.
Results
DAC-TP is an allosteric activator and substrate of SAMHD1.
DAC-TP and AZA-TP both contain the same modified nucleo-
base that closely resembles cytosine, except for the carbon at
position 5 of the base that is replaced with a nitrogen atom. The
only difference between these two nucleotide analogs is that
DAC-TP contains a 2′-deoxyribose sugar, while AZA-TP pos-
sesses a ribose sugar with a 2′-hydroxyl group (Fig. 1a).
Neither AZA-TP nor DAC-TP were hydrolyzed by SAMHD1
in the absence of additional activators in an in vitro enzymatic
assay, suggesting that they cannot bind both allosteric sites to
activate the enzyme (Fig. 1b). However, when GTP was added to
the mixture, DAC-TP (but not AZA-TP) was hydrolyzed by
SAMHD1 just as efficiently as canonical dCTP (Fig. 1c). As GTP
can only bind the A1 site18, this implies that DAC-TP can occupy
the A2 site to activate SAMHD1-mediated hydrolysis. In an
established SAMHD1 pre-assembly assay17,18, SAMHD1 tetra-
mers were pre-assembled in the presence of dGTP and
subsequently diluted into either reaction buffer alone or buffer
containing dCTP, DAC-TP, or AZA-TP (Fig. 1d). dCTP and
DAC-TP, but not AZA-TP, were hydrolyzed, confirming that
DAC-TP, but not AZA-TP, is a substrate of SAMHD1 enzyme.
To confirm our finding that DAC-TP can promote SAMHD1
tetramerization by binding to the A2 site, we monitored the
oligomerization state of SAMHD1 in the presence of the A1-site
activator GTP following addition of either DAC-TP or AZA-TP.
Size-exclusion chromatography revealed that DAC-TP, but not
AZA-TP, induced the formation of higher-order SAMHD1
oligomers (Fig. 1e). In line with these results, the sedimentation
velocity measured by an analytical ultracentrifugation assay
confirmed that DAC-TP, but not AZA-TP, induces the formation
of SAMHD1 tetramers (Fig. 1f).
To elucidate how DAC-TP binds the catalytic pocket and
A2 site of SAMHD1, DAC-TP was co-crystallized with the
inactivated catalytic domain of SAMHD1 (residues 113–626
with H206R and D207N mutations), which has been extensively
used to study nucleotide binding to SAMHD117,18. The crystal
structure of the complex, determined at a 2 Å resolution
(Supplementary Table 1), demonstrated that DAC-TP mole-
cules can occupy both the A2 pockets and catalytic sites of the
SAMHD1 tetramer (Fig. 1g). Comparison of the DAC-TP/
SAMHD1 structure (PDB ID code 6CM2) with a previously
determined dCTP/SAMHD1 structure (PDB ID 4TNP)18
showed that the two structures align very well with an overall
root-mean-square deviation of ~0.4 Å. The hydrogen-bonding
interactions between the SAMHD1 catalytic pocket and DAC-
TP are the same as those involved in dCTP binding. Although
an additional water molecule forms a hydrogen bond with the
position five nitrogen moiety that is only present in the base of
DAC-TP, this extra water molecule, interestingly, did not
engage in any interaction with SAMHD1. Moreover,
SAMHD1’s catalytic pocket was not altered by the interaction
with DAC-TP, suggesting that DAC-TP adopts a binding mode
similar to that of canonical dCTP (Fig. 1g, lower inset). In line
with our biochemical analyses (Fig. 1b–d), AZA-TP did not co-
crystallize with SAMHD1. Taken together, DAC-TP is an
allosteric activator and substrate of SAMHD1, while AZA-TP
does not interact with SAMHD1 (Supplementary Fig. 2c).
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SAMHD1 expression controls DAC-TP levels and cytotoxicity.
To investigate whether SAMHD1 expression may differentially
affect the cytotoxicity of DAC and AZA, we tested their effects in
a panel of human AML cell lines with differential SAMHD1
expression (Fig. 2a). In addition, we included the investigational
drug SGI-110 in these analyses. SGI-110 is a dinucleotide of DAC
and deoxyguanosine, which is intracellularly converted to DAC
and has shown promising preclinical and clinical activity8. The
activity of these three drugs against AML cell lines was
determined by the half-maximal inhibitory concentration (IC50).
We found that levels of SAMHD1 protein (Fig. 2a) and SAMHD1
mRNA (Supplementary Fig. 3) were inversely correlated with
cytotoxicity of DAC and SGI-110, but not of AZA (Fig. 2b,
Supplementary Figs 4, 5, 6a, b, and Supplementary Table 2).
Notably, the IC50 values of DAC correlated with those of SGI-110
(Supplementary Fig. 6c), but not with those of AZA (Supple-
mentary Fig. 6d) or of non-nucleoside cancer drugs, including the
topoisomerase II inhibitors daunorubicin and etoposide, the
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Fig. 1 DAC-TP, but not AZA-TP, is an allosteric activator and substrate of SAMHD1. a Chemical structures of dCTP, decitabine triphosphate (DAC-TP), and
azacytidine triphosphate (AZA-TP). b–d dNTPase activity assay for recombinant SAMHD1. The rate of hydrolysis for the indicated nucleotide
triphosphates was quantified in the presence of (b) buffer alone, (c) GTP, which can occupy allosteric site 1 (A1), or (d) dGTP, which can occupy A1 and
allosteric site 2 (A2). Cat: Catalytic site. e Size-exclusion chromatograms of SAMHD1 in absence of nucleotide (yellow line) or in the presence of GTP
alone (gray dashed line), DAC-TP alone (orange dashed line), GTP+DAC-TP (orange line), GTP+AZA-TP (blue line), or GTP+ dCTP (black line).
f Sedimentation velocity of SAMHD1 incubated in the presence of GTP in combination with either AZA-TP or DAC-TP. g Structure of the SAMHD1
tetramer in complex with DAC-TP. Each SAMHD1 subunit is shown as a surface representation, colored in light pink, deep teal, light green and wheat. In
the insets, nucleotides are shown as sticks. (Top, right panel) An overlay of SAMHD1 structures in complex with dCTP (PDB ID: 4TNP; gray) or DAC-TP
(light pink) in allosteric site 2. (Bottom, right panel) An overlay of SAMHD1 structures in complex with dCTP (PDB ID: 4TNP; gray) or DAC-TP (deep teal)
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topoisomerase I inhibitors topotecan, and the alkylating agents
lomustine and melphalan (Supplementary Fig. 7).
Next, intracellular DAC-TP and AZA-TP concentrations were
measured by liquid chromatography-coupled tandem mass
spectrometry (LC–MS/MS) in AML cell lines displaying varying
SAMHD1 levels. DAC-TP, but not AZA-TP, concentrations
correlated with drug efficacy (Fig. 2c). Moreover, SAMHD1
protein levels were inversely correlated with DAC-TP, but not
AZA-TP, concentrations (Fig. 2d). In addition, SAMHD1 levels
correlated with endogenous dNTP concentrations, but no correla-
tion was observed between the antileukemic efficacy of DAC or
AZA and the cellular dNTP concentrations (Supplementary Fig. 8).
The levels of other proteins involved in either HMA uptake
(including the human equlibrative nucleoside transporter (hENT1;
SLC29A1) and the ergothioneine transporter (OCTN1)) or HMA
metabolism (including deoxycytidine kinase (DCK), uridine-
cytidine kinase 1 and 2 (UCK1 and UCK2), cytidine deaminase
(CDA), deoxycytidilate deaminase (DCTD), and RNR large and
small subunit (RNR1 and RNR2)) (Supplementary Fig. 1)9,25 did
not correlate with the cytotoxic activity of either AZA or DAC in
AML cell lines (Supplementary Figs 9 and 10). Collectively, these
results further confirm that the antileukemic potency of DAC, but
not of the structurally closely related AZA, is correlated to
SAMHD1 triphosphohydrolase activity in AML cell lines.
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Interestingly, SAMHD1 phosphorylation at threonine 592
(T592) was detected in most AML cell lines (Fig. 2a), although
T592 phosphorylation had in the past been suggested to be
primarily associated with a loss of triphosphohydrolase activity
during the S-phase of the cell cycle26–28. Our results are more in
line with findings by Tramentozzi et al., which showed that the
enzymatic function of SAMHD1 can remain active during the
entire cell cycle irrespectively of its phosphorylation status29.
Modulation of SAMHD1 expression affects DAC efficiency.
Next, we investigated the impact of SAMHD1 deficiency on DAC
activity by different approaches: (i) CRISPR–Cas9-mediated
SAMHD1 gene disruption in AML cell lines exhibiting high
endogenous SAMHD1 levels, (ii) SAMHD1 knockdown using
lentiviral vectors encoding shRNA, or (iii) targeted degradation of
SAMHD1 with virus-like particles (VLPs) that shuttle the
SAMHD1-interacting lentiviral Vpx protein (Vpx-VLPs) into
cells19. Vpx recruits SAMHD1 to a cullin4A-RING E3 ubiquitin
ligase (CRL4DCAF1), which targets SAMHD1 for proteasomal
degradation28. In AML cells, SAMHD1 knockout (THP-1 KO),
SAMHD1 knockdown (OCI-AML3), and SAMHD1 depletion by
transduction with Vpx-VLPs (THP-1 and OCI-AML3) markedly
increased the efficacy of DAC treatment (3.5–37-fold), but not of
AZA treatment (1.2–1.6-fold) (Fig. 3a, b; Supplementary Fig. 11).
Similarly, the DAC-based dinucleotide SGI-110 showed enhanced
cytotoxicity in SAMHD1-deficient cells (Supplementary Fig. 12).
Next, we constitutively expressed wild-type SAMHD1
(SAMHD1-WT) or the triphosphohydrolase-defective mutant
SAMHD1-D311A19 in HEL cells, which are characterized by low
SAMHD1 levels (Supplementary Fig. 13a). Constitutive expres-
sion of SAMHD1-WT, but not of SAMHD1-D311A, decreased
the cytotoxicity of DAC and SGI-110, but not of AZA
(Supplementary Fig. 13b-d). Furthermore, DAC-TP levels (and
to a lesser extent endogenous dNTPs; Supplementary Fig. 14a)
were elevated in SAMHD1-deficient THP1 KO cells compared
with THP-1 control cells (Fig. 3c), while AZA-TP levels were not
increased upon ablation of SAMHD1 (Fig. 3d). Similar drug and
dNTP responses were observed in the SAMHD1
triphosphohydrolase-functional and -defective HEL cell lines
(Supplementary Figs 13e,f and 14b).
About 10–35% of AZA can be converted into DAC-TP11,12
(Supplementary Fig. 1). Consequently, DAC-TP was readily
detectable in AZA-treated THP-1 KO cells, but, interestingly,
hardly detectable in AZA-treated THP-1 control cells (Supple-
mentary Fig. 15a). Similarly, DAC-TP was readily found in AZA-
treated parental HEL cells and HEL cells expressing the
catalytically inactive SAMHD1-D311A, while being barely
detectable in HEL SAMHD1-WT cells (Supplementary Fig. 15b).
These results show that SAMHD1’s triphosphohydrolase activity
controls the intracellular DAC-TP levels following both DAC and
AZA treatment of AML cells, while AZA-TP levels are not
affected.
Effects of SAMHD1 on DAC-induced apoptosis and DNA
damage. Next, we explored the degree to which SAMHD1 may
influence DNA damage and apoptosis induction by DAC and
AZA. In THP-1 KO cells, DAC treatment elicited an enhanced
concentration-dependent DNA damage response compared with
THP-1 control cells, as indicated by increased levels of phos-
phorylated histone H2AX (ser139) (ɣH2AX), phosphorylated
Chk2 (Thr68), and phosphorylated TIF1β (ser824) (Fig. 3e, right
panels). Similarly, enhanced levels of apoptosis, as indicated by
PARP1 cleavage (Fig. 3e) and increased fractions of sub-G1 cells
(Supplementary Fig. 16a), were observed at lower concentrations
of DAC in SAMHD1-deficient THP-1 KO cells compared with
THP-1 control cells. In AZA-treated THP-1 cells, SAMHD1
exerted less pronounced effects on phosphorylated ɣH2AX, Chk2,
TIF1β, cPARP1, and sub-G1 cells, which were only observed at
the highest AZA concentrations in THP-1 KO cells (Fig. 3e, left
panels and Supplementary Fig. 16b).
DAC and AZA may promote DNA damage through induction
of DNA DSBs resulting in repair processes including non-
homologous end joining and/or HR11,30,31. SAMHD1 was
recently shown to facilitate HR-mediated DSB repair indepen-
dently of its triphosphohydrolase function by promoting DNA
end resection through direct interaction with MRE11/CtIP and
stimulation of their nuclease activity23,32. In human carcinoma
and osteosarcoma cell lines, SAMHD1 overexpression decreased
the efficacy of DSB-inducing drugs such as topoisomerase
inhibitors or IR, while SAMHD1 depletion was associated with
increased efficacy of these treatments23. To investigate a potential
role of triphosphohydrolase-independent SAMHD1 effects on the
antileukemic drug activity, we first studied the impact of
SAMHD1 on the toxicity of non-nucleoside DSB-inducing drugs
that do not depend on SAMHD1’s triphosphohydrolase activity.
The topoisomerase II inhibitors daunorubicin or etoposide, the
topoisomerase I inhibitor topotecan, and the alkylating agents
lomustine or melphalan showed similar cytotoxicity and induced
markers of DNA damage and apoptosis at similar concentrations
in THP-1 KO and THP-1 control cells, irrespective of their
SAMHD1 status (Supplementary Figs 16c, and 17-19). Next, we
tested whether overexpression of the SAMHD1 mutants D207N
and D311A, which are both characterized by disrupted tripho-
sphohydrolase function but sustained nuclease-promoting
activity23,33,34, in HEL cells may alleviate the efficacy of HMAs
or non-nucleoside drugs including daunorubicin and lomustine.
Only SAMHD1-WT significantly decreased toxicity of DAC, but
not of AZA or any other triphosphohydrolase activity-
independent agents, while SAMHD1 mutants D311A and D207
did not influence the activity of any of these drugs including DAC
(Fig. 3f and Supplementary Fig. 20). To test whether inhibition of
enzymes involved in HR other than SAMHD1 may influence the
activity of HMAs, parental HEL cells and HEL cells expressing
either SAMHD1-WT or the triphosphohydrolase-deficient
mutants were treated with the RAD51 inhibitor B0231,35, which
prevents HR downstream of MRE11/CtIP/SAMHD1 activity23,32.
In line with previous reports31,35, B02 markedly increased toxicity
of DAC, AZA, and lomustine (Fig. 3g), confirming that
interference with HR can in principle affect the antileukemic
activity of these drugs. Together, these data suggest that
SAMHD1 does not significantly influence the efficacy of HMAs
through its nuclease-promoting functions in AML cells.
SAMHD1 regulates DAC-TP-mediated methylation changes.
DNA (cytosine-5)-methyltransferase 1 (DNMT1) depletion and
changes in global DNA methylation induced by DAC and AZA
were investigated in the THP-1 model cell lines. Incorporation of
DAC-TP into DNA results in the formation of adducts between
DNA and DNMT1, which are degraded by the proteasome,
resulting in decreased DNA methylation9,10. Therefore, DNMT1
depletion and suppression of global DNA methylation may be
used as downstream surrogates for bioactive DAC-TP levels.
DAC-induced DNMT1 depletion (Fig. 3e, right panels) and
suppressed DNA methylation (Supplementary Fig. 21a) at lower
concentrations in THP-1 KO cells compared with THP-1 control
cells. The maximum effect of DAC on DNA methylation was
achieved at a concentration of 0.08 µM in THP-1 KO cells
(Supplementary Fig. 21a). AZA affected DNMT1 levels and DNA
methylation only at higher drug concentrations than DAC. Again,
these effects were more pronounced in THP-1 KO cells than in
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11413-4 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3475 | https://doi.org/10.1038/s41467-019-11413-4 |www.nature.com/naturecommunications 5
SAMHD1-expressing cells (Fig. 3e, left panels and Supplementary
Fig. 21b). Together, this indicates that SAMHD1 also affects
demethylation caused by AZA-derived DAC-TP.
AML cell adaptation to HMAs results in SAMHD1 upregula-
tion. Next, we explored the potential role of SAMHD1 in
acquired resistance formation to HMAs. SAMHD1-low-
expressing HL-60 cells were gradually adapted over a period of
at least 6 months to proliferation in the presence of either DAC
(1 µM) or AZA (10 µM), concentrations that are within the range
of clinically achievable steady-state plasma levels of these HMAs
(DAC: 0.3–1.6 µM; AZA: 3–11 µM)36–38. Short-term (3 days)
exposure of parental HL-60 cells with DAC or AZA did not result
in increased SAMHD1 expression, although DNMT1 levels and
global DNA methylation were already found to be suppressed
(Supplementary Fig. 22). In contrast, all three long-term selected,
AZA-resistant (rAZA; I–III) and rDAC HL-60 sublines displayed
increased SAMHD1 expression at the protein (Fig. 4a) and
mRNA levels (Supplementary Fig. 23). rDAC sublines were
highly resistant to DAC (Fig. 4b), but not or only marginally
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Fig. 3 SAMHD1 triphosphohydrolase activity controls DAC response. a, b IC50 values for (a) DAC or (b) AZA in AML cell lines THP-1 and OCI-AML3 with
experimentally modulated SAMHD1 levels. SAMHD1 was depleted by either CRISPR/Cas9-mediated SAMHD1 knockout in THP-1 cells (THP-1 KO), by
shRNA-mediated silencing of SAMHD1 in OCI-AML3 cells, or by transduction with VLPs carrying SAMHD1-degrading Vpx protein (Vpx-VLPs). Unedited
THP-1 cells (THP-1 Ctr.), cells transduced with control-shRNAs (shCTRL), or cells treated with Vpr-carrying VLPs (Vpr-VLPs) served as controls. Each
point represents an average of three technical replicates, and in each case, as shown, three independent experiments were performed. Horizontal lines
and error bars represent means ± s.d. The numbers above the data points indicate the factor of decrease of IC50 values in SAMHD1-depleted cells
relative to control cells. Representative SAMHD1 immunoblots for the different experimental conditions are shown. β-Actin served as a loading control.
c, d Representative LC–MS/MS analyses of (c) DAC-TP levels or (d) AZA-TP levels in THP-1 Ctr. or THP-1 KO cells. e Representative immunoblots of
proteins involved in DNA damage response and DNA methylation in THP-1 Ctr. or THP-1 KO cells following treatment with increasing concentrations (0,
0.08, 0.4, 2, and 10 µM) of either AZA (left panels) or DAC (right panels) for 72 h. f, g IC50 values of (f) DAC, AZA and daunorubicin or (g) DAC, AZA
and lomustine without or with the RAD51 inhibitor B02 in parental HEL cells and HEL cells overexpressing either SAMHD1-WT or the dNTPase-defective
SAMHD1 mutants SAMHD1-D311A or SAMHD1-D207N. Each closed circle represents a technical replicate (n= 3) of one representative experiment out of
three. Horizontal lines and error bars represent mean ± s.d. Numbers indicate the factor of decrease of IC50 values in SAMHD1-depleted relative to control
cells. Statistical analyses were performed using unpaired two-tailed Students’ t-test. **p < 0.01; ***p < 0.001
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resistant to AZA (Fig. 4c). In contrast, HL-60 cells adapted to
AZA displayed considerable cross-resistance to DAC, ranging
from 35- to 58-fold (Fig. 4b, c). Targeted degradation of
SAMHD1 using Vpx-VLPs sensitized both rDAC and rAZA HL-
60 sublines, but not parental HL-60 cells, to DAC-induced
cytotoxicity (Fig. 4d, upper panel). This differential response was
mirrored by the respective intracellular DAC-TP levels (Fig. 4e).
In contrast, the cytotoxic response to AZA (Fig. 4d, lower panel)
and AZA-TP levels (Fig. 4f) were unaffected by Vpx-VLP expo-
sure and SAMHD1 depletion. Collectively, these results suggest
that long-term treatment of AML cells with HMAs, the bioactive
metabolites of which are fully (DAC) or only in part (AZA)
SAMHD1-dependent, results in SAMHD1-overexpressing leu-
kemic cells. We also observed that the sublines rDACI to III
displayed decreased levels of DCK compared with parental HL-60
cells. In addition, rDACI and II cells, but not rDACIII, displayed
increased CDA levels (Fig. 4a). The sublines rAZAI to III dis-
played increased levels of DCTD in addition to enhanced CDA
levels (Fig. 4a). These differences indicate that HL-60 adaptation
to DAC and AZA can, in addition to SAMHD1 upregulation, be
associated with further resistance mechanisms that partly differ
between the individual HMA-resistant sublines.
Cellular SAMHD1 levels may be regulated by mechanisms,
including DNA promoter methylation, proteasomal SAMHD1
degradation, and autophagy39–41. We tested whether SAMHD1
overexpression in HL-60 sublines resistant to DAC or AZA may
be associated with demethylation of the SAMHD1 gene promoter.
PCR amplification of genomic DNA treated with the
methylation-sensitive HpaII endonuclease revealed a single PCR
product corresponding to the size of the SAMHD1 promoter (1
kb) in both HpaII treated and untreated parental HL-60 cells
indicating methylation of the promoter (Fig. 4g), but not in
genomic DNA from rDAC HL-60 and THP-1 cells, which served
as a control for an unmethylated SAMHD1 promoter40. This
shows that the SAMHD1 promoter is primarily in an unmethy-
lated state in HL-60 cells with acquired resistance to DAC.
Interestingly, the SAMHD1 promoter appeared to be primarily in
a methylated state in rAZA HL-60 sublines (Fig. 4g), albeit the
global DNA methylation was suppressed in both rAZA HL-60
and rDAC HL-60 sublines to a similar extent (Fig. 4h). These
results indicate that different molecular mechanisms underlie
SAMHD1 overexpression during AZA and DAC resistance
formation.
SAMHD1 predicts DAC response in AML xenotransplant
models. To investigate whether SAMHD1 expression differen-
tially influences the anti-tumor activity of DAC and AZA
in vivo, immunodeficient NSG mice, transplanted with the
human AML cell lines genetically engineered to express different
levels of SAMHD1, were treated with these HMAs. Mice
transplanted with THP-1 KO cells survived significantly longer
than mice transplanted with THP-1 control cells in response to
DAC (Fig. 5a, b). In contrast, no SAMHD1 dependency was
observed in the survival of AZA-treated (Fig. 5c) or PBS-treated
mice (Fig. 5b, c). In line with these findings, mice bearing HEL
SAMHD1-D311A xenografts survived significantly longer than
their HEL SAMHD1-WT-bearing counterparts, when treated
with DAC, but not with AZA or PBS (Fig. 5d–f and Supple-
mentary Fig. 24).
SAMHD1 determines the clinical response to DAC in AML.
Primary leukemic cells were isolated and enriched from the bone
marrow of therapy-naive AML patients (for patients’ character-
istics see Supplementary Data file 1). Basal SAMHD1 protein
expression levels, quantified by flow cytometry (Supplementary
Fig. 25a, b), were correlated with the IC50 values of the dNTPase-
sensitive drugs, Ara-C and DAC (P= 0.0002 and P= 1.0 × 10−6,
respectively), but not of AZA (P= 0.1567) (Fig. 6a–c). Next, we
evaluated the effects of SAMHD1 depletion by either Vpx-VLPs
or siRNA in blasts of four AML patients (Supplementary Data
file 1; patients A–D). Transient reduction of SAMHD1 in blasts
lowered the IC50 values for DAC by 2.7–9.3-fold (Fig. 6d),
whereas sensitivity to AZA was largely unaffected (Fig. 6e). In
addition, Vpx-VLP- and siRNA-mediated SAMHD1 depletion
did not increase the toxicity of the non-nucleoside drug dau-
norubicin in the blasts of patients B and C (Fig. 6f, g).
Finally, we examined whether SAMHD1 protein levels in
leukemic blasts may represent a biomarker for predicting the
response to DAC-based therapy. AML blasts in sections of
paraffinized bone-marrow specimens taken at primary diagnosis
from a multi-centric cohort of adult AML patients, 55 of which
received first-line DAC monotherapy and 48 of which received
first-line AZA monotherapy (detailed patient characteristics are
listed in Supplementary Data file 2), were retrospectively analyzed
for SAMHD1 protein levels in blasts by immunohistochemical
(IHC) staining and histopathological evaluation in a blinded
manner. SAMHD1 levels were markedly increased in the DAC-
treated patients, who did not achieve complete remission
(progressive disease and stable disease summarized as ‘No CR’)
(Fig. 6h, i). In contrast, SAMHD1 levels were not correlated with
clinical response in AZA-treated patients (Fig. 6h, j). Of the 55
DAC-treated patients, 19 achieved a CR as best response. Fifteen
of these 19 patients were scored as ‘SAMHD1 low’ (IHC score of
0 or 1, 79%, Fig. 6i) and 4 were scored as ‘SAMHD1 high’ (IHC
score of 2 or 3, 21%, Fig. 6i) (P= 0.012 by chi-squared test with 1
degree of freedom). No significant difference was observed
between ‘SAMHD1 low’ and ‘SAMHD1 high’ patients in the
AZA-treated cohort (P= 1, Fig. 6j).
Discussion
Our study identified SAMHD1 as a predictive biomarker and a
therapeutic target for DAC-based, but not AZA-based therapy, in
AML (Fig. 7). Importantly, these findings may also contribute to
the mechanistic understanding of previously reported
preclinical11,42 and clinical results6,43,44 that showed differences
in efficacy and initial response rates between these two drugs,
which are often regarded as interchangeable therapeutic options
in AML5–7.
A recent report by Knecht et al. has provided detail on the
determinants of nucleoside analog triphosphate interactions with
the catalytic and allosteric sites of SAMHD1 via the Watson-
Crick edge of the base and the sugar and phosphate groups and
identified 2’-sugar modifications as a major determinant of
nucleotide analog binding to SAMHD120. The allosteric A2 site
was only permissive to 2′-deoxyribose-based (e.g., cladribine-TP)
nucleotide analogs, but not to arabinose-based (e.g., cytarabine-
TP and fludarabine-TP) or 2′-deoxy-2′-fluororibose-based (i.e.,
clofarabine-TP) nucleotide analogs. Nucleoside analog tripho-
sphates with modifications at the 2′ sugar position, which bind
only to the catalytic site, require the presence of other (canonical)
nucleotides to induce SAMHD1 tetramerization and activity
(Supplementary Fig. 2b). In accordance, our current results show
that the 2′-deoxyribose nucleotide DAC-TP (but not the ribose
nucleotide AZA-TP) binds to both the allosteric A2 and the
catalytic site of SAMHD1, being both a substrate and an activator
of the enzyme (Supplementary Fig. 2c). Importantly, our data also
demonstrate that a modification at the Hoogsteen edge, the
introduction of a nitrogen atom in 5 position of the cytosine base,
does not affect DAC-TP binding to SAMHD1 compared with
dCTP (Supplementary Fig. 26).
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About 10–35% of administered AZA become metabolized into
DAC-TP11,12. In accordance, we detected substantial amounts of
DAC-TP in AZA-treated SAMHD1-deficient AML cells, but only
DAC-TP traces in SAMHD1-expressing cells. This indicates that
AZA is indeed partially converted into DAC-TP in AML cells and
that this AZA-derived DAC-TP is subject to SAMHD1-mediated
hydrolysis. In line with these data, DAC-TP-dependent activities of
AZA, such as DNMT1 depletion and changes in global DNA
methylation, were inhibited by SAMHD1. However, SAMHD1 was
not found to interfere with AZA activity in AML cell lines, primary
leukemic blasts, and xenotransplanted mice. Moreover, the AZA
response of AML patients did not correlate with the SAMHD1
levels in leukemic cells. This indicates that the therapeutic effects of
AZA are primarily caused by other mechanisms than conversion
into AZA-derived DAC-TP in AML. In accordance, recent clinical
investigations in MDS and chronic myelomonocytic leukemia
patients reported a lack of correlation between AZA activity and
AZA metabolization into DAC-TP45.
Recently, SAMHD1 was shown to promote repair of (che-
motherapy-induced) DNA DSBs by HR, independently of its tri-
phosphohydrolase function23,32. However, our results do not
indicate a significant relationship between SAMHD1 and HMA
toxicity in AML cells through this mechanism. Moreover,
SAMHD1 hydrolyzes and depletes endogenous dNTPs, which has
been described to induce replication stress and to increase sensi-
tivity to cytotoxic drugs46. However, we observed that high
SAMHD1 levels were associated with low DAC-induced cytotoxi-
city, although they had also resulted in reduced endogenous dNTP
concentrations. Consequently, SAMHD1 interferes with the action
of DAC predominantly via hydrolysis of DAC-TP in AML cells.
In our models of acquired resistance, the DAC- and AZA-
adapted HL-60 sublines displayed multifactorial resistance
mechanisms that partially differed between the individual sublines,
as indicated by varying expression of HMA-metabolizing enzymes
(i.e., DCK, CDA, and DCTD), which have been reported previously
to contribute to HMA resistance14,42. Interestingly, both DAC- and
AZA-adapted HL-60 sublines displayed increased SAMHD1 levels
and triphosphohydrolase activity. Since SAMHD1 directly inacti-
vates DAC-TP, it does not come as a surprise that its upregulation
represents an acquired DAC resistance mechanism. In AZA-
adapted cells, however, the origin of the SAMHD1 upregulation is
less intuitive. In a previous study, low DAC doses, which did not
cause acute cytotoxic effects, nevertheless elicited antileukemic
effects after long-term treatment47. Low DAC-TP levels resulting
from AZA metabolization, which do not acutely affect AML cell
viability, may thus still affect AML cells after long-term exposure.
Hence, the increased SAMHD1 levels observed in AZA-adapted
cells are likely to be the consequence only of the selection pressure
exerted by long-term AML cell exposure to low levels of AZA-
derived DAC-TP.
Several biomarkers have been proposed to predict response to
HMAs, including mutations in genes coding for the epigenetic
enzymes DNMT3A, IDH1/2, TET2, ASXL1, or the tumor sup-
pressor TP5313,14. However, none of these candidate biomarkers
appears to be sufficiently robust to guide a personalized HMA
selection. Our retrospective IHC investigations indicate that
SAMHD1 has potential to serve as a biomarker to predict the AML
response to DAC (and SGI-110). The expression analyses of spe-
cific proteins in tissue sections by IHC is typically based on visual
scoring, semi-quantitative by nature and difficult to standardize,
despite an evaluation by experienced histopathologists. It has to be
noted, however, that IHC scoring is already part of the diagnostic
standard work-up in several tumors, including breast, brain, and
lung cancers, e.g., in the latter to quantify PD1/PD-L1 expression
to guide checkpoint inhibitor therapy48. Moreover, qPCR-based or
flow cytometry-based quantification of SAMHD1 mRNA or pro-
tein levels, respectively, were similarly predictive as IHC scoring of
AML blast responses to Ara-C in previous studies19,22. SAMHD1
mutations seem to be rare in AML patients49 and are, hence, not
suitable as biomarker for DAC therapy.
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In conclusion, our findings demonstrate that the activity of
DAC, but not of AZA, is affected by the triphosphohydrolase
activity of SAMHD1 in AML cells. This indicates substantial
differences in the mode of action of these HMAs that are often
regarded to be interchangeable in AML therapy. More research
will be needed to identify biomarkers that reliably guide the
decision on whether patients should be treated with DAC or
AZA. Based on our data, however, SAMHD1 has the potential to
become a relevant biomarker for the stratification of HMAs in
AML patients and a therapeutic target for the improvement of
DAC- and SGI-110-based therapies.
Methods
Protein expression and purification. N-terminal 6 × His-tagged SAMHD1 con-
structs were expressed in Escherichia coli BL21(DE3). Cells were harvested,
resuspended in lysis buffer (50 mM Tris, pH 8, 500 mM NaCl, 20 mM imidazole, 5
mM MgCl2, 0.5 mM TCEP), and lysed using a microfluidizer. Lysate was clarified
by centrifugation (26,892 × g for 25 min). SAMHD1 protein was purified using Ni-
NTA affinity and size-exclusion chromatography in SAMHD1 buffer (50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 5 mM MgCl2, and 0.5 mM TCEP).
Analytical size-exclusion chromatography. Purified samples of SAMHD1 (2 mg
per ml, 50 μl) mixed with a final concentration of 500 µM GTP and 2–4 mM
nucleotide analog were applied to a Superdex 200 5/150 GL column (GE Health-
care) pre-equilibrated with SAMHD1 buffer. The UV absorbance at 280 nm was
measured as the protein sample eluted from the column, and values were nor-
malized to their respective peak heights.
Analytical ultracentrifugation (AUC). Sedimentation velocity experiments were
performed with a Beckman XL-I analytical ultracentrifuge. Samples were prepared
with protein concentration of 0.8–1.3 mg/ml in SAMHD1 buffer and equilibrated
with a final concentration of 150 μM nucleotides. AUC was performed at
169,167 × g and 20 °C with an An60-Ti rotor. The experimental parameters
including sample partial specific volume, buffer density and viscosity were calcu-
lated with SEDNTERP (http://sednterp.unh.edu/). Velocity data were analyzed
with the program SEDFIT50.
Crystallization and data collection. SAMHD1 protein in buffer (50 mM Tris-HCl
(pH 8.0), 150 mM NaCl, 5 mM MgCl2, and 0.5 mM TCEP) was mixed with 1 mM
GTP and 10mM nucleotide analogs and incubated at 4 °C for 15 min before
crystallization. All crystals were grown at 25 °C using the microbatch under-oil
method by mixing 1 μL protein (5 mg per ml) with 1 μL crystallization buffer (100
mM SPG (Qiagen), pH 7.4, 25% PEG 1500). Crystals were cryoprotected by
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Fig. 6 SAMHD1 expression is a predictive biomarker for DAC therapy in AML. a–c Correlative analyses of SAMHD1 expression and cytotoxicity for (a) Ara-
C, (b) DAC, or (c) AZA was performed in bone-marrow-derived blasts from therapy-naive AML patients (blast purities of > 80%). SAMHD1 expression
was analyzed by flow cytometry. IC50 measurements were determined in parallel. Data were analyzed by using a generalized log-logistic model. The r2
value indicates goodness-of-fit of the regression model to the data, and represents variance explained by the independent variable divided by total variance
of the IC50 values for Ara-C. d, e Blasts from four AML patients were either transduced with Vpx- or Vpr-VLPs or left untreated (no VLPs; patients A, B), or
transfected with SAMHD1-specific or control siRNAs (patients C, D), and 2 days later, analyzed for cytotoxicity induced by (d) AZA or (e) DAC. SAMHD1
expression was analyzed by immunoblotting. Horizontal lines and error bars represent means ± s.d. of the IC50 values. Circles represent single values of
one technical triplicate for each patient. The numbers above the data points indicate the factor by which the SAMHD1-depleted and the control groups
differed. Statistical analyses were performed using unpaired two-tailed Students’ t test. f, g Dose–response analyses in patients transduced either with Vpx-
or Vpr-VLPs (patient B), or transfected with SAMHD1-specific or control siRNAs (patient C) and subsequently treated with different concentrations of
daunorubicin and incubated for 96 h before viability was quantified by MTT analyses. Values are mean ± s.d. of triplicates of one technical experiment.
h Representative IHC micrographs showing SAMHD1 expression in bone marrow (BM) from patients on DAC- or AZA-based therapy with complete
remission (CR) (#300, #340) or progressive disease (#297, #312). BM from two healthy donors is shown as reference. Scale bars, 100 μm. i, j Shown are
relative frequencies of patients with IHC scores of 0, 1, 2, or 3 among CR and no-CR patients who had received monotherapy with either (i) DAC or
(j) AZA. The bar for no-CR patients is subdivided into patients with stable disease (left side) and progressive disease (right side) patients
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crystallization buffer supplemented with 25% (vol/vol) glycerol before being frozen
in liquid nitrogen. Diffraction data were collected at the Advanced Photon Source
beamline 24-IDC. The data statistics are summarized in Supplementary Table 1.
Structure determination and refinement. The structures were solved by mole-
cular replacement using PHASER51. The previously published SAMHD1 tetramer
structure, with all bound nucleotides removed was used as the search model (PDB
ID 4BZB). The model was refined with iterative rounds of TLS and restrained
refinement using Refmac552, followed by rebuilding the model to the 2Fo–Fc and
the Fo–Fc maps using Coot53. Refinement statistics are summarized in Supple-
mentary Table 1.
Malachite green colorimetric assay. The enzymatic activity assay was modified
from Seamon and Stivers (2015)54. All assays were performed with purified wild-
type SAMHD1 (residues 113–626) at 25 °C in a reaction buffer containing 50 mM
Tris-HCl pH 8, 150 mM NaCl, 5 mM MgCl2, and 0.5 mM TCEP. Each 40 µL
reaction, containing 10 µM pyrophosphatase, 0.5 µM SAMHD1, and 125 µM
substrate or allosteric activator was quenched with 40 µL 20 mM EDTA after 15
min. Then, 20 µL Malachite green reagent was added to the solution and developed
for 15 min before the absorbance at 650 nm was measured.
Cell Lines and primary AML blasts. The human AML cell lines THP-1, OCI-
AML2, OCI-AML3, Molm13, PL-21, HL-60, MV4-11, SIG-M5, ML2, NB4, KG1,
MonoMac6, and HEL were obtained from DSMZ (Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH). THP-1 cells deficient in SAMHD1
(THP-1 KO) and control cells (THP-1 Ctr.) were generated using a CRISPR/Cas9
approach55.
THP-1 cells were plated at a density of 2 × 105 cells per ml. After 24 h, 2.5 × 106
cells were resuspended in 250 µl Opti-MEM, mixed with 5 µg CRISPR/Cas plasmid
DNA, and electroporated in a 4-mm cuvette using an exponential pulse at 250 V
and 950 mF utilizing a Gene Pulser electroporation device (Bio-Rad Laboratories).
We used a plasmid encoding a CMV-mCherry-Cas9 expression cassette and a
human SAMHD1 gene specific gRNA driven by the U6 promoter. An early coding
exon of the SAMHD1 gene was targeted using the following gRNA construct: 5′-
CGGAAGGGGTGTTTGAGGGG-3′. Cells were allowed to recover for 2 days in 6-
well plates filled with 4 ml medium per well before being FACS sorted for
mCherry-expression on a BD FACS Aria III (BD Biosciences). For subsequent
limiting dilution cloning, cells were plated at a density of 5, 10, or 20 cells per well
of nine round-bottom 96-well plates and grown for 2 weeks. Plates were scanned
for absorption at 600 nm and growing clones were identified using custom software
and picked and duplicated by a Biomek FXp (Beckman Coulter) liquid handling
system.
For shRNA-mediated silencing of SAMHD1, OCI-AML3 cells were transduced
by spinoculation with VSV-G pseudotyped lentiviral vectors carrying either
pLKO.1-puro-control-shRNA or pLKO.1-puro-SAMHD1-shRNA56.
OCI-AML3 stable cell lines were generated by transduction with lentiviral
vectors encoding unspecific shRNA (pLKO-nontarget) or shRNA specific to
SAMHD1 (shSAMHD1 TRCN0000343807: sequence: CCGGCCCTGAAGAAGAT
ATTTGCTTCTCGAGAAGCAAATATCTTCTTCAGGGTTTTTG) (Sigma) and
selected with puromycin.
The HEL SAMHD1-WT and HEL SAMHD1-D311A cell lines were generated
by co-transfection of the packaging vector pPAX2 (Addgene), either pHR-
SAMHD1-WT or pHR-SAMHD1-D311A and a plasmid encoding VSV-G57.
DAC- or AZA-resistant cell sublines were established by the continuous exposure
of parental (DAC/AZA sensitive) HL-60 cell line to increasing drug
concentrations19, and are part of the Resistant Cancer Cell Line (RCCL) collection
(http://www.kent.ac.uk/stms/cmp/RCCL/RCCLabout). Briefly, cells were cultured
at increasing AZA or DAC concentrations starting with the concentrations that
inhibited viability of the parental cell lines by 50% (IC50). HMA concentrations
were doubled every 2–6 weeks until cells readily grew in the presence of 10 µM and
1 µM AZA or DAC, respectively.
All cell lines were routinely tested for Mycoplasma, using the MycoAlert PLUS
assay kit from Lonza, and were authenticated by short tandem repeat profiling, as
described elsewhere58.
Mononuclear cells from blood or bone-marrow AML samples were purified by
Ficoll-Hypaque gradient centrifugation. Leukemic cells were enriched by negative
selection with a combination of CD3-, CD19- and CD235a-microbeads (all
obtained from Miltenyi Biotec) according to the manufacturer’s instructions and
separated by the autoMACS™ Pro Separator. All preparations were evaluated for
purity, resulting in > 90% leukemic blasts.
All AML cell lines were cultured in IMDM (Biochrom) supplemented with 10%
FBS (SIG-M5 20% FBS, Sigma-Aldrich), 4 mM L-glutamine (Sigma-Aldrich), 100
IU per ml penicillin (Sigma-Aldrich), and 100 mg per ml streptomycin (Sigma-
Aldrich) at 37 °C in a humidified 5% CO2 incubator. AML blasts were cultivated in
IMDM (Biochrom) supplemented with 10% FBS, 4 mM L-glutamine, 25 ng per ml
hTPO, 50 ng per ml hSCF, 50 ng per ml hFlt3-Ligand, and 20 ng per ml hIL3 (all
obtained from Miltenyi Biotec) in 5% CO2 and 37 °C.
Manipulation of SAMHD1 through siRNA and Vpx-VLPs. For siRNA-mediated
silencing, AML blasts (1.2 × 106) were transfected with 2.5 µM ON-TARGET plus
human SAMHD1 siRNA SMART-pool obtained from Dharmacon in resuspension
electroporation buffer R (Invitrogen) using the Neon transfection system
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(Invitrogen) according to the manufacturer’s recommendation. In addition, ON-
TARGET plus Non-targeting Pool (Dharmacon) was transfected in parallel. The
electroporation was performed with one 20 ms pulse of 1700 V and analyzed 48 h
after transfection by western blotting and a cell viability assay. The following
siRNA duplexes were used: non-targeting (UGGUUUACAUGUCGACUAA;
UGGUUUACAUGUUGUGUGA; UGGUUUACAUGUUUUCUGA;
UGGUUUACAUGUUUUCCUA), SAMHD1 (GACAAUGAGUUGCGUAUUU;
CAUGUUUGAUGGACGAUUU; AAGUAUUGCUAGACGUGAA; UUAG
UUAUAUCCAGCGAUU)19. AML cell lines and primary AML blasts were spi-
noculated with VSV-G pseudotyped VLPs carrying either Vpx or Vpr from SIV-
mac25119. Briefly, VLPs, carrying either Vpx or Vpr from SIVmac251, were
produced by co-transfection of 293T cells with pSIV3+ gag pol expression plas-
mids and a plasmid encoding VSV-G. The SAMHD1 degradation capacity of Vpx-
VLPs was determined in THP-1 cells 24-h post transduction by intracellular
SAMHD1 staining.
Compounds. 5-Aza-2′-deoxycytidine (DAC) and B02 was purchased from Sigma-
Aldrich, 5-azacytidine (AZA), Ara-C, and Daunorubicin from Tocris, Melphalan
from Aspen, Topotecan from Novartis, Etoposide from Teva GmbH, and
Lomustine was obtained from Santa Cruz. SGI-110 and dNs were obtained from
Sigma-Aldrich59. All nucleotide standards and internal standards for the LC–MS/
MS analysis were obtained from Sigma-Aldrich, Silantes or Alsachim. Labeled 5-
azacytidine and 5-aza-2′-deoxycytidine, 5-azacytidine-15N4 and 5-aza-2′-deox-
ycytidine-15N4, for LC–MS/MS analysis were manufactured by Toronto Research
Chemicals.
Cell viability assay. The viability of AML cell lines treated with various drug
concentrations was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) dye reduction assay60. For AML blasts ex vivo
endpoint viability assays were performed using the CellTiter-Glo (Promega) assay
according to the manufacturer’s protocol. The amount of ATP is directly pro-
portional to the number of cells present in culture. Briefly, cells were seeded at 5000
cells per well (10,000 cells per well for MTT dye) in 96-well plates and treated for
96 h with compounds, over a range of concentrations. Then the assay was termi-
nated and luminescence was measured on a Tecan infinite M200 (TECAN) or for
MTT dye at a wavelength of 560 nm (reference wavelength 620 nm). IC50 values
were calculated by using CalcuSyn from Biosoft.
Flow cytometry. The intracellular SAMHD1 staining was performed as previously
described. Staining for surface markers (CD33, CD34, CD45) for AML blasts was
applied before fixation. The following fluorochrome-conjugated antibodies were
used: CD33-PE and CD34-FITC, both from Miltenyi Biotech, CD45-V450 from
BD Pharmingen, all diluted 1:11 per 1 × 107 cells, and Alexa-Fluor-660 from
Invitrogen, Life Technologies, 1:200). Samples were analyzed by using a FACS-
Verse or FACSCanto II flow cytometer from BD Biosciences and the FlowJo
software from TreeStar.
Western blotting. For western blotting19, cells were lysed in Triton X-100 sample
buffer and proteins separated by sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis. Proteins were blotted on a nitrocellulose membrane (Thermo
Scientific).
The following primary antibodies were used at the indicated dilutions:
SAMHD1 (Proteintech, 1:1000), β-actin (BioVision via BioCat, 1:2000), DCK
(Santa Cruz, 1:500), CDA (Santa Cruz, 1:100), ENT1 (Abcam, 1:500), and UCK1
(Thermo Scientific, 1:1000), UCK2 (Thermo Scientific, 1:1000), RRM1 (Santa Cruz,
1:1000), RRM2 (Santa Cruz, 1:1000), OCTN1 (Abnova, 1:1000), cPARP (,1:2000),
yH2AX (Cell Signaling, 1:2000), Chk2 (Cell Signaling, 1:1000), pChk2 (Cell
Signaling, 1:1000), SAMHD1 (ProteinTech, 1:2000), TIF1β (Cell Signalling,
1:1000), pTIF1β (Cell Signaling, 1:1000), DNMT1 (Active Motif, 1:1000).
Visualization and quantification were performed by using peroxidase-labeled
secondary antibodies (Calbiochem) and enhanced chemiluminescence
(SuperSignal West FEMTO Substrate; Thermo Scientific) or IRDye-labeled
secondary antibodies (LI-COR Biotechnology) according to the manufacturer’s
instructions. Band volume analysis was conducted by Odyssey LICOR. Uncropped
scans of the blots are provided as Source Data file.
mRNA analyses. RNA extraction and TaqMan-based mRNA quantification of
SAMHD1 (assay no. Hs00210019_m1) and RNaseP (TaqMan® RNase P Control
Reagents Kit (4316844)) as endogenous reference control were performed
according to the manufactures protocol (Applied Biosystems)61. Total RNA was
extracted using the RNeasy Kit from Qiagen and stored at −80 °C until use.
Relative quantitative PCR analyses were performed on the ABI Prism
7500 sequence detection system (Applied Biosystems). SAMHD1 mRNA expres-
sion levels were quantified by using the ΔΔCt method with RNaseP mRNA as an
endogenous reference control. All samples were run in triplicate. Data analysis was
conducted using the 7500 System Software (Applied Biosystems).
LC–MS/MS analysis. AML cells were seeded at 5 × 105 cells per well in 24-well
plates, treated with labeled 15N4-AZA or 15N4-DAC and incubated at 37 °C in a
humidified 5% CO2 incubator for 6 h. Subsequently, cells were washed twice in 1
ml PBS, pelleted and stored at −80 °C until measurement. The concentrations of
dNTPs, 15N4-AZA-TP, and 15N4-DAC-TP in the samples were analyzed by liquid
chromatography–electrospray ionization–tandem mass spectrometry62. Briefly, the
analytes were extracted by protein precipitation with methanol. An anion-exchange
HPLC column (BioBasic AX, 150 × 2.1 mm, 5 µM, Thermo Scientific) was used for
the chromatographic separation and a 5500 QTrap (Sciex) was used as analyzer,
operating as triple quadrupole in positive multiple reaction monitoring (MRM)
mode. The analysis of the dNTP was performed as previously described62. In
addition, 15N4-AZA-TP or 15N4-DAC-TP were quantified using cytidine-13C9,
15N3-triphosphate (13C9,15N3-CTP) or 2-deoxycytidine-13C9,15N3-triphosphate
(13C9,15N3-dCTP) as internal standard (IS). The precursor-to-product ion transi-
tions used as quantifiers were m/z 473.1→ 117.0 for 15N4-DAC-TP and m/z
489.0→ 117.1 for 15N4-AZA-TP. Owing to the lack of commercially available
standards for 15N4-AZA-TP and 15N4-DAC-TP, relative quantification was per-
formed by comparing the peak area ratios (analyte/IS) of the differently treated
samples.
Apoptosis assay. Sub-G1 cells as a marker for DNA fragmentation in late
apoptotic cells were measured according to Nicoletti by flow cytometry63. Briefly,
Aza- or DAC-treated and untreated cells were washed once in 1× PBS, incubated
for at least 2 h at 4 °C with Nicoletti buffer (0.1% trisodiumcitrate-dihydrate pH
7.4, 0.1% Triton X-100, 50 µg/ml propidium iodide), and diluted before mea-
surement in 1× PBS. Samples were analyzed with a FACSVerse (BD Biosciences)
and FlowJo software (TreeStar).
Global DNA methylation assay. For the detection of differences in global DNA
methylation, the ELISA-based global DNA methylation—LINE-1 kit from Active
Motif was used. The assay was performed in triplicates using DNA samples from
THP-1 KO and THP-1 control cells after treatment with AZA or DAC according to
the manufacturer’s instructions. The colorimetric readout was quantified on a
spectrophotometer (Tecan infinite M200, TECAN) at 450 nm with a reference
wavelength of 655 nm.
DNA methylation analyses of the SAMHD1 promoter. SAMHD1 promoter
contains five HpaII sites surrounding the transcription start site40. Methylation of
the HpaII sites in the SAMHD1 promoter would prevent digestion by the HpaII,
and the intact sequence would serve as a template for PCR amplification using
SAMHD1 promoter-specific primers that flank the HpaII sites. To measure
methylation of the SAMHD1 promoter genomic DNA was treated with the
methylation-sensitive HpaII endonuclease or left untreated as described previously
with some modifications40. PM3.fwd: TTCCGCCTCATTCGTCCTTG and PM3.
rev: GGTTCTCGGGCTGTCATCG were used as SAMHD1 promoter-specific
primers. A single PCR product (993-bp) corresponding to the SAMHD1 promoter
sequence was obtained from untreated genomic DNA and treated DNA from cells
with methylated but not from cells with unmethylated SAMHD1 promoter. To
serve as input control, a 0.25-kb fragment of the GAPDH gene lacking HpaII sites
was PCR-amplified using the same template DNA40.
Mice. Female non-obese diabetic severe combined immunodeficient gamma (NSG)
mice were purchased from Jackson ImmunoResearch laboratories (Ban Harbor,
ME). All mice used in the experiments were between 6 and 10 weeks of age. All
animal experiments were performed according to the regulations of the United
Kingdom Home Office and German authorities.
Xenograft mouse model. In total, 0.2 × 106 THP-1 or HEL cells were intrave-
nously injected into NSG mice through the tail vein as described elsewhere64. Ten
days after leukemia cell injection, the mice were given either vehicle control or
decitabine (0.4 mg per kg, i.p., twice a week) for 4 weeks or azacytidine (either 5 mg
per kg, i.v., twice a week for 4 weeks, or 2.5 mg per kg, 5× per week with 1 week
drug pause between weeks 2 and 3). Mice were monitored closely for clinical signs
of leukemia such as weight loss, hind-limb paralysis. Blood was drawn for blood-
counts analysis to confirm leukemia.
Patients. Patients were admitted to the Frankfurt and Münster University Hos-
pitals between 2012 and 2017 and were treated for newly diagnosed AML with
regimens containing standard dose decitabine or azacytidine. In addition, viable
AML cells were purified from the bone marrow of patients who were admitted to
the University Hospital Frankfurt in 2016 and 2017. Patients at the Frankfurt and
Münster University Hospitals are routinely advised to undergo a bone-marrow
biopsy at diagnosis. All patients consented to the scientific analyses of their data
and of biomaterial obtained for diagnostic purposes. All patients gave informed
consent according to the Declaration of Helsinki to participate in the collection of
samples. The use of whole blood and bone marrow aspirates was approved by the
Ethics Committee of Frankfurt University Hospital (approval no. SHN-11-2016
and SHN-03-2017) and University Hospital Muenster (approval no. 2007-390-f-S).
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For the analyses, patient records were reviewed by physicians who were unaware of
the SAMHD1 expression results in the diagnostic biopsies. Remission criteria and
cytogenetic risk groups were assessed according to the ELN guidelines. The best
response to DAC or AZA therapy was analyzed in bone-marrow biopsies and
aspirates and defined as complete (CR) if the blast count was < 5%, and as “no CR”
if the blast count was > 5%. Material is available on request.
Immunostaining of bone marrow samples. Tissues were fixed in 4% buffered
formalin, descaled by EDTA and embedded in paraffin. For immunohistochemical
staining19. Two micrometers of bone marrow tissue sections were incubated with
EnVision Flex Target Retrieval Solution, pH low (K8005, DAKO) and stained with
primary antibodies directed against SAMHD1 (12586-1-AP, Proteintech, 1:3000)
and against CD34 (IR632, DAKO) for 40 min at room temperature. Polymeric
secondary antibodies coupled to HRPO peroxidase and DAB were used for
visualization (REAL EnVision Peroxidase/DAB+, K5007, DAKO). Tissue samples
were analyzed by light microscopy after counterstaining with Meyer’s hematoxylin
(K8008, DAKO). Two pathologists, who were blinded to clinical history and
therapeutic response, independently scored the SAMHD1 IHCs. They evaluated all
tissue sections for nuclear SAMHD1 staining using a four-stage staining score: 0=
negative; 1=weak intensity of staining; 2= strong intensity of staining in <25% of
blasts; and 3= strong intensity of staining in more than 25% of blasts. IHC staining
scores of 0 and 1 were defined as ‘no or low expression’ and IHC staining scores of
2 and 3 were defined as ‘high SAMHD1 expression’. Membranous CD34 staining
for the quantification of the number of AML blasts was evaluated using a two-stage
staining score: 0= negative; 1= positive.
Statistics. Statistical data analysis was performed in R, version 3.3.2. Population
means were compared using Student’s t-test if data were approximately normally
distributed or the rank-sum test as a non-parametric alternative otherwise. Survival
analyses were performed using the Kaplan–Meier estimator, assessing statistical
significance of survival differences using the logrank test. Pearson’s correlation
coefficient was used to compute correlations between variables, using a t-test to
assess significance of the correlation. Dose–response curves were analyzed using
the drm package in R, using the logistic and log-logistic models. A likelihood-ratio
(chi-squared) test was used to assess model significance and goodness of fit.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The atomic coordinates and structure factors have been deposited in the Protein Data
Bank, www.pdb.org (PDB ID code 6CM2). The source data underlying Figs 3–6 and
Supplementary Figs 3–27 are provided as a Source Data file. All the other data supporting
the findings of this study are available within the article and its supplementary
information files and from the corresponding author upon reasonable request. A
reporting summary for this article is available as a Supplementary Information file.
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